BACKGROUND: Although the incidence of adenocarcinoma of the esophageal and gastroesophageal junction has increased at an alarming rate in the past 30 years, little improvement has been made in treatment strategies. Previous studies have demonstrated that many upper gastrointestinal (GI) adenocarcinomas exhibit ERBB2 amplification. In cancers proven to have similar amplification, such as breast, ERBB2-targeted therapies have dramatically improved overall survival and disease-free rates of survival. This study uses siRNA to knockdown ERBB2 in GI adenocarcinoma cell lines to evaluate cell viability, apoptosis, and changes in cell cycle. METHODS: A cell line with a baseline amount of ERBB2 (Seg-1) and 2 upper GI adenocarcinoma cell lines with known amplification of ERBB2 (esophageal [OE19] and gastric [MKN45]) were treated with 120 pmol of 1 of 2 independent ERBB2 siRNAs or control siRNA for 6 hours. RESULTS: We demonstrate that knockdown of ERBB2 in esophageal and gastric cancer cell lines with known ERBB2 amplification effectively decreases ERBB2 protein levels and decreases cell viability mainly via apoptotic pathways. CONCLUSION: ERBB-directed therapy may be of benefit in the subset of patients with GI adenocarcinomas exhibiting amplification of ERBB2.
BACKGROUND: Although the incidence of adenocarcinoma of the esophageal and gastroesophageal junction has increased at an alarming rate in the past 30 years, little improvement has been made in treatment strategies. Previous studies have demonstrated that many upper gastrointestinal (GI) adenocarcinomas exhibit ERBB2 amplification. In cancers proven to have similar amplification, such as breast, ERBB2-targeted therapies have dramatically improved overall survival and disease-free rates of survival. This study uses siRNA to knockdown ERBB2 in GI adenocarcinoma cell lines to evaluate cell viability, apoptosis, and changes in cell cycle. METHODS: A cell line with a baseline amount of ERBB2 (Seg-1) and 2 upper GI adenocarcinoma cell lines with known amplification of ERBB2 (esophageal [OE19] and gastric [MKN45]) were treated with 120 pmol of 1 of 2 independent ERBB2 siRNAs or control siRNA for 6 hours. RESULTS: We demonstrate that knockdown of ERBB2 in esophageal and gastric cancer cell lines with known ERBB2 amplification effectively decreases ERBB2 protein levels and decreases cell viability mainly via apoptotic pathways. CONCLUSION:ERBB-directed therapy may be of benefit in the subset of patients with GI adenocarcinomas exhibiting amplification of ERBB2.
Authors: M Tanner; M Hollmén; T T Junttila; A I Kapanen; S Tommola; Y Soini; H Helin; J Salo; H Joensuu; E Sihvo; K Elenius; J Isola Journal: Ann Oncol Date: 2005-02 Impact factor: 32.976
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: H Safran; M Steinhoff; S Mangray; R Rathore; T C King; L Chai; K Berzein; T Moore; D Iannitti; P Reiss; T Pasquariello; P Akerman; D Quirk; R Mass; L Goldstein; U Tantravahi Journal: Am J Clin Oncol Date: 2001-10 Impact factor: 2.339
Authors: Mathew Casimiro; Olga Rodriguez; Llana Pootrakul; Maral Aventian; Nadia Lushina; Caroline Cromelin; Georgina Ferzli; Kevin Johnson; Stanley Fricke; Fantahun Diba; Bhaskar Kallakury; Chioma Ohanyerenwa; Maxine Chen; Michael Ostrowski; Mien-Chie Hung; Shafaat A Rabbani; Ram Datar; Richard Cote; Richard Pestell; Chris Albanese Journal: Cancer Res Date: 2007-05-01 Impact factor: 12.701
Authors: Peter S Dahlberg; Lance F Ferrin; Suzanne M Grindle; Curtis M Nelson; Chuong D Hoang; Blake Jacobson Journal: Ann Thorac Surg Date: 2004-03 Impact factor: 4.330
Authors: Charles T Miller; Justin R Moy; Lin Lin; Matthew Schipper; Daniel Normolle; Dean E Brenner; Mark D Iannettoni; Mark B Orringer; David G Beer Journal: Clin Cancer Res Date: 2003-10-15 Impact factor: 12.531
Authors: Chin-Tung Chen; Hyaehwan Kim; David Liska; Sizhi Gao; James G Christensen; Martin R Weiser Journal: Mol Cancer Ther Date: 2012-01-11 Impact factor: 6.261